Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Eisai Inc. Stories

2012-05-17 10:25:58

WOODCLIFF LAKE, N.J., May 17, 2012 /PRNewswire/ -- Eisai announced today that 15 abstracts highlighting new study results will be presented during the 48(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from June 1 to June 5, 2012. These studies highlight Eisai's current product portfolio and oncology pipeline, reinforcing the company's commitment to patients and their families affected by cancer. "Our human health care mission is to help...

2012-05-10 14:22:28

SAN DIEGO and WOODCLIFF LAKE, N.J., May 10, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the lorcaserin marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. Lorcaserin is an investigational drug candidate intended for weight management. In addition to the United States, the territories in the expanded agreement now include most of...

2012-05-10 10:26:27

SAN DIEGO and WOODCLIFF LAKE, N.J., May 10, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 18 to 4, with one abstention, that the available data demonstrate that the potential benefits of lorcaserin outweigh the potential risks when used long-term in a population of overweight and obese individuals. Lorcaserin is an investigational drug...

2012-04-30 02:26:03

WOODCLIFF LAKE, N.J., April 30, 2012 /PRNewswire/ -- Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Allen Waxman to the position of Senior Vice President and General Counsel. In this position, Mr. Waxman will lead the Office of the General Counsel, where he will be responsible for all legal matters for the company in the U.S. Mr. Waxman will be a member of the company's Executive Committee and will also join others in providing leadership for...

2012-04-30 02:26:00

CAMBRIDGE, England and CAMBRIDGE, Mass., April 30, 2012 /PRNewswire/ -- Horizon Discovery Ltd (Horizon), a leading provider of research tools to support the development of personalized medicines, and H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of oncology treatments, today announced they have entered into a collaboration agreement to identify and validate a panel of novel cancer drug targets. (Logo:...

2012-04-24 02:29:04

New Treatment Option Significantly Prolongs Overall Survival in Pre-treated Metastatic Breast Cancer Patients MISSISSAUGA, ON, April 24, 2012 /PRNewswire/ - Eisai Limited, a wholly-owned Canadian subsidiary of Eisai Inc., announced today the launch of Halaven(TM) (eribulin mesylate), the latest treatment approved by Health Canada for metastatic breast cancer.  Halaven(TM) is indicated for the treatment of patients with metastatic breast cancer who have previously received at...

2012-04-19 18:20:20

WOODCLIFF LAKE, N.J., April 20, 2012 /PRNewswire/ -- Eisai announced today that the company has amended the licensing agreement with Teikoku Pharma USA, Inc. (TPU), a subsidiary of Teikoku Seiyaku Co., Ltd., pertaining to exclusive overseas marketing rights for the Aricept® patch (once weekly donepezil HCl transdermal system). (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO) The amendment allows TPU to be solely responsible for making all decisions regarding future...

2012-04-18 10:24:44

WOODCLIFF LAKE, N.J., April 18, 2012 /PRNewswire/ -- Eisai Inc. announced today that the results of the study, "Randomized Phase III Study 306: Adjunctive Perampanel for Refractory Partial-Onset Seizures," were published online today in the April 18, 2012, edition of Neurology®. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO) Marketing authorization applications for perampanel are currently under review with the U.S. Food and Drug Administration and the...

2012-04-16 02:28:44

EXTON, Pa., April 16, 2012 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 in the treatment of metastatic colorectal cancer that is refractory to all standard therapy. MORAb-004 is a monoclonal antibody that specifically binds to endosialin/tumor endothelial marker-1 (TEM-1). The trial is a randomized, double-blind, placebo-controlled study to assess the...

2012-03-27 02:27:47

EXTON, Pa., March 27, 2012 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today it has completed enrollment of the FAR-131 clinical trial. The study is a pivotal Phase 3 randomized trial of farletuzumab in first-relapsed patients with platinum-sensitive ovarian cancer. Farletuzumab is a humanized monoclonal antibody that targets folate receptor alpha (FRA), which is expressed on the majority of non-mucinous epithelial ovarian cancers as well as a subset of other...